Rising political support from both state and national governments for funding in research activities and providing subsidies along with tax waivers is escalating the anti-parkinson’s drugs market size over the foreseeable time line. Additionally, upsurge in public awareness, ageing population, and rising health insurance will further promote in industry revenue generation till 2027.
The global anti-Parkinson’s drugs market should reach US$ 6 billion by 2028 at a CAGR 6%.
Technological advancements such as 3-D printing solutions, wearable technologies, mobile applications, and biomarkers for monitoring and treating patients diagnosed with Parkinson’s disease will aid in enhancing the industry share between 2022 and 2027. Over 10 million of the population across the globe gets diagnosed with Parkinson’s disease annually of which approximately 60,000 are Americans. Thus, rising prevalence of the Parkinson’s disease will improve the industry size.
Global anti-parkinson’s drugs market is segmented based on the product as, Dopaminergic, Dopamine Agonist, and Enzyme Inhibitors. Global anti-parkinson’s drugs market report covers various regions including North America, Europe, Asia Pacific, and Rest of World. The regional anti-parkinson’s drugs market is further bifurcated for major countries including U.S., Canada, Germany, UK, France, Italy, China, India, Japan, Brazil, South Africa and others.
Competitive Rivalry
Global anti-parkinson’s drugs market share consists of several players AbbVie, GlaxoSmithKline, Mylan Labs, Novartis, Valeant Pharmaceuticals, and Zambon Pharmaceuticals.
The Anti-Parkinson’s Drugs Market has been segmented as below:
Anti-Parkinson’s Drugs Market, By Product
Anti-Parkinson’s Drugs Market, By Region
The report covers:
Report scope:
The global anti-parkinson’s drugs market report covers detailed study with the underlying influencing factors for the variations in the industry growth trends.
The report scope includes market analysis on regional as well as country level. The report also provides competitive landscape covering company market shares with detailed profiling for major revenue contributing companies.
The report covers a detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include AbbVie, GlaxoSmithKline, Mylan Labs, Novartis, Valeant Pharmaceuticals, and Zambon Pharmaceuticals.
Reasons to Buy this Report:
Customization:
Customized report as per the requirement can be offered with appropriate recommendations
Below are our New Reports :-
1. Introduction
1.1. Key Points
1.2. Report Description
1.3. Markets Covered
1.4. Stakeholders
2. Research Methodology
2.1. Research Scope
2.2. Research Methodology
2.2.1. Market Research Process
2.2.2. Research Methodology
2.2.2.1. Secondary Research
2.2.2.2. Primary Research
2.2.2.3. Models for Estimation
2.3. Market Size Estimation
2.3.1. Bottom-Up Approach
2.3.2. Top-Down Approach
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Drivers
4.2.1. Government initiatives
4.2.2. Major associations
4.3. Restraints
4.3.1. Shortage of skills
4.3.2. Stringent regulations and long approval procedures
4.4. Opportunities
4.4.1. Technological advancements
4.4.2. Internet penetration and mobile applications
4.5. Challenges
4.5.1. Existence of traditional medicines
5. Anti-Parkinson’s Drugs Market, By Product
5.1. Key Points
5.2. Dopaminergic
5.3. Dopamine Agonist
5.4. Enzyme Inhibitors
5.5. Others
6. Competitive Landscape
6.1. Introduction
6.2. Recent Developments
6.2.1. Mergers & Acquisitions
6.2.2. New Product Developments
6.2.3. Portfolio/Production Capacity Expansions
6.2.4. Joint Ventures, Collaborations, Partnerships & Agreements
6.2.5. Others
7. Company Profile
7.1. AbbVie
7.1.1. Company Overview
7.1.2. Product/Service Landscape
7.1.3. Financial Overview
7.1.4. Recent Developments
7.2. GlaxoSmithKline
7.2.1. Company Overview
7.2.2. Product/Service Landscape
7.2.3. Financial Overview
7.2.4. Recent Developments
7.3. Mylan Labs
7.3.1. Company Overview
7.3.2. Product/Service Landscape
7.3.3. Financial Overview
7.3.4. Recent Developments
7.4. Novartis
7.4.1. Company Overview
7.4.2. Product/Service Landscape
7.4.3. Financial Overview
7.4.4. Recent Developments
7.5. Valeant Pharmaceuticals
7.5.1. Company Overview
7.5.2. Product/Service Landscape
7.5.3. Financial Overview
7.5.4. Recent Developments
7.6. Zambon Pharmaceuticals
7.6.1. Company Overview
7.6.2. Product/Service Landscape
7.6.3. Financial Overview
7.6.4. Recent Developments
The Anti-Parkinson’s Drugs Market has been segmented as below:
Anti-Parkinson’s Drugs Market, By Product
Anti-Parkinson’s Drugs Market, By Region
